Contact us  to learn more about
our Premium Content:  News alerts, weekly reports and conference planners

FoundationOne® CDx

FDA Approved
Related tests:
FoundationOne CDx is the first FDA-approved broad companion diagnostic (CDx) to detect genetic mutations in 324 genes and two genomic signatures in any solid tumor. It is clinically and analytically validated for solid tumors, including: NSCLC, Colorectal, Breast, Ovarian, and Melanoma. The test is designed to provide physicians with clinically actionable information - both to consider appropriate therapies for patients and understand results with evidence of resistance - based on the individual genomic profile of each patient’s cancer.
Biliary Tract Cancer, Breast Cancer, Cholangiocarcinoma, Colorectal Cancer, Melanoma, Non Small Cell Lung Cancer, Ovarian Cancer, Prostate Cancer, Solid Tumor
AKT1 (V-akt murine thymoma viral oncogene homolog 1), ALK (Anaplastic lymphoma kinase), ATM (ATM serine/threonine kinase), BARD1 (BRCA1 Associated RING Domain 1), BRAF (B-raf proto-oncogene), BRCA1 (Breast cancer 1, early onset)
See More ...
Akeega (abiraterone/niraparib), Alecensa (alectinib), Alunbrig (brigatinib), Braftovi (encorafenib), Cotellic (cobimetinib), Erbitux (cetuximab), Gilotrif (afatinib), Herceptin (trastuzumab), Kadcyla (ado-trastuzumab emtansine), Keytruda (pembrolizumab), Lynparza (olaparib), Mekinist (trametinib), Mektovi (binimetinib), Pemazyre (pemigatinib), Perjeta (pertuzumab), Piqray (alpelisib), Retevmo (selpercatinib), Rozlytrek (entrectinib), Rubraca (rucaparib), Rybrevant (amivantamab-vmjw), Tabrecta (capmatinib), Tafinlar (dabrafenib), Tagrisso (osimertinib), Talzenna (talazoparib), Truqap (capivasertib), Truseltiq (infigratinib), Vectibix (panitumumab), Vitrakvi (larotrectinib), Vizimpro (dacomitinib), Xalkori (crizotinib), Zelboraf (vemurafenib), Zykadia (ceritinib), erlotinib, gefitinib
Next-Generation Sequencing (NGS)